Pediatric Urology and Regenerative Medicine Research Center, Section of Tissue Engineering and Stem Cells Therapy, Children's Hospital Medical Center, Tehran University of Medical Sciences, No. 62, Dr. Gharib's Street, Keshavarz Boulevard, Tehran, 1419433151, Iran.
Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Stem Cell Rev Rep. 2022 Feb;18(2):752-767. doi: 10.1007/s12015-021-10150-w. Epub 2021 Mar 19.
Neural tube defects (NTDs) are among the most common congenital defects during neurulation. Spina bifida is a type of NTD that can occur in different forms. Since myelomeningocele (MMC) is the most severe form of spina bifida, finding a satisfactory treatment for MMC is a gold standard for the treatment of spina bifida. The Management of Myelomeningocele Study (MOMS) demonstrated that intrauterine treatment of spina bifida could ameliorate the complications associated with spina bifida and would also reduce the placement of ventriculoperitoneal (VP) shunt by 50%. Recently developed tissue engineering (TE) approaches using scaffolds, stem cells, and growth factors allow treatment of the fetus with minimally invasive methods and promising outcomes. The application of novel patches with appropriate stem cells and growth factors leads to better coverage of the defect with fewer complications. These approaches with less invasive surgical procedures, even in animal models with similar characteristics as the human MMC defect, paves the way for the modern application of less invasive surgical methods. Significantly, the early detection of these problems and applying these approaches can increase the potential efficacy of MMC treatment with fewer complications. However, further studies should be conducted to find the most suitable scaffolds and stem cells, and their application should be evaluated in animal models. This review intends to discuss advanced TE methods for treating MMC and recent successes in increasing the efficacy of the treatment.
神经管缺陷(NTDs)是神经发生过程中最常见的先天性缺陷之一。脊柱裂是 NTD 的一种类型,可呈现不同的形式。由于脊髓脊膜膨出(MMC)是最严重的脊柱裂形式,因此找到治疗 MMC 的满意方法是治疗脊柱裂的金标准。神经管缺陷宫内治疗研究(MOMS)表明,宫内治疗脊柱裂可以改善与脊柱裂相关的并发症,并将脑室腹腔(VP)分流术的放置减少 50%。最近开发的使用支架、干细胞和生长因子的组织工程(TE)方法允许采用微创方法治疗胎儿,并具有有前景的结果。具有适当干细胞和生长因子的新型补片的应用可导致更好地覆盖缺陷,并发症更少。这些方法具有更少的侵入性手术程序,即使在与人类 MMC 缺陷具有相似特征的动物模型中,也为现代应用微创方法铺平了道路。重要的是,早期发现这些问题并应用这些方法可以提高 MMC 治疗的潜在疗效,同时减少并发症。然而,应该进行进一步的研究以找到最合适的支架和干细胞,并在动物模型中评估其应用。本综述旨在讨论治疗 MMC 的先进 TE 方法以及最近在提高治疗效果方面的成功。